Johnson & Johnson

Declining short interest in Alexion Pharmaceuticals (NASDAQ: ALXN) and Pharmacyclics (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical companies between the August 15 and August 30 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Biogen...

Insiders may sell shares for any number of reasons, but conventional wisdom says that insiders really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have...

Among leading biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw significant percentage declines in short interest between the July 31 and August 15 settlement dates. Short sellers also shied away...

The analysts at UBS have added Nordstrom (NYSE: JWN) and Stanley Black & Decker (NYSE: SWK) to their Dividend Rulers list. Two consumer goods companies already on the UBS list are Clorox (NYSE: CLX) and Johnson & Johnson (NYSE: JNJ). UBS selects stocks for its Dividend Ruler list based...

Don’t expect to get a direct answer from any of the big pharma firms, but in the world of big data, the answer, or something pretty close to answer, was found by doing some simple math. Last year, Forbes columnist Matthew Herper went back to the basics and simply divided each company’s spending...

Eli Lilly & Co. (NYSE: LLY) planned to go back to the drawing board with its new experimental Alzheimer’s drug, according Bloomberg. The drug, solanezumab, which was not successful with advanced Alzheimer’s patients, will be tested in patients who show signs of early stages of the disease...

The earnings season ramps up this week, providing plenty of perspective on how the financial and technology sectors fared in the second quarter. Bank of America (NYSE: BAC), Citigroup (NYSE: C), Goldman Sachs (NYSE: GS), Google (NASDAQ: GOOG), Intel (NYSE: INTC), Microsoft (NASDAQ: MSFT) and many...

The new earnings season kicks off this week with the traditional first report from Alcoa (NYSE: AA) on Monday afternoon. The first of the big banks, J.P. Morgan (NYSE: JPM) and Wells Fargo (NYSE: WFC), close out the week when they step into the earnings spotlight Friday morning. Analysts predict...

This weekend in Barron's online: the world's most respected companies, a special report on what is next for the markets, and the prospects for Kansas City Southern and the Dole Food buyout. Cover Story "World's Most Respected Companies" by Vito J. Racanelli. After topping Barron's annual...

Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest between the May 31 and June 14 settlement dates. The number of shares sold short in Onyx Pharmaceuticals (NASDAQ: ONXX), Pharmacyclics (NASDAQ: PCYC) and Regeneron...

Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), saw the most significant rise in short interest between the May 15 and May 31 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Dendreon (NASDAQ: DNDN), Onyx Pharmaceuticals (NASDAQ: ONXX)...

Two oil and gas companies -- CVR Energy (NYSE: CVI) and W&T Offshore (NYSE: WTI) -- were among the top performing dividend-paying stocks in May. So were drug maker Warner Chilcott (NASDAQ: WCRX) and semiconductor company Himax Technologies (NASDAQ: HIMX). Below we take a glance at how these...

Among biotech and emerging pharmaceutical companies, Regeneron Pharmaceuticals (NASDAQ: REGN) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw he most significant rise in short interest between the April 30 and May 15 settlement dates. The number of shares sold short in Alexion Pharmaceuticals (...

It’s a sign of the times in health care. If you can’t generate growth, buy it. The New York Times sounded that familiar theme in reporting the pending acquisition Monday of Rochester, N ew York-based Bausch & Lomb by Canadian drugmaker Valeant Pharmaceuticals (NYSE: VRX). J. Michael...

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April. The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX) and VIVUS (NASDAQ: VVUS)...